Because AOD-9604 does not bind to growth hormone receptors in liver, muscle, or adipose tissue, it cannot trigger the metabolic pathways that mediate growth hormones counter-regulatory effects on glucose metabolism
Do not flush unused medications or pour down a sink or drain
The published data shows meaningful but modest fat loss in clinical conditions, approximately 1 to 2 kg of additional fat loss over 12 weeks compared to placebo at 1 mg/day
For patients with neurological involvement, maintenance injections are typically given every 2 months
AOD 9604 is typically used during fasted states and is compatible with intermittent fasting protocols
Research Guide Available , read the science, mechanism, and research data for this compound